10 completed, 4 unknown, 3 not yet recruiting, 2 recruiting. 21 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 10, Unknown 4, Not yet recruiting 3, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 3 | 4 | Unknown 3, Withdrawn 1 |
Follow Immunosuppression: new trials by email Literature Review of Immunosuppression trials Research Report on Immunosuppression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (TNX-1500) in Kidney Transplant Recipients TNX-1500, Kidney Transplant - Kidney Transplant, Kidney Transplant Failure and Rejection | Phase 2 | Not yet recruiting | Ayman Al Jurdi, MD | 5 | 2026-11-01 | 2026-08-19 |
| NAI for Sepsis With Persistent Lymphopenia Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC) - Sepsis, Septic Shock | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-07-06 | 2026-05-11 |
| Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer Histamine Dihydrochloride (HDC), Interleukin-2 (IL-2) - Pancreatic Cancer, Surgery | Phase 2 | Not yet recruiting | Sahlgrenska University Hospital | 50 | 2024-04-01 | 2023-11-22 |
| Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations NVX-CoV2372 - Immunosuppression, COVID-19 | Phase 2 | Completed | University of Wisconsin, Madison | 21 | 2023-11-20 | 2025-10-20 |
| High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients mRNA-1273 (Moderna COVID-19 vaccine) - Lung Transplant Recipient, SARS-CoV-2 | Phase 1 / Phase 2 | Terminated | University of California, Los Angeles | 19 | 2022-03-10 | 2025-03-26 |
| COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases COVID-19 vaccine - Rheumatoid Arthritis, Autoimmune Rheumatologic Disease | Phase 2 / Phase 3 | Unknown | Paul R Fortin | 287 | 2022-03-09 | 2023-01-17 |
| Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis Sirolimus - Lupus Nephritis, Immunosuppression | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 20 | 2021-06-30 | 2021-05-19 |
| Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease Maintenance or reduction of immunosuppression - COVID, Kidney Transplant; Complications | Phase 2 / Phase 3 | Withdrawn | Brigham and Women's Hospital | 2021-05-03 | 2022-05-04 | |
| Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases AntiSARS-CoV-2 Serum, Placebo - Immunosuppression, Cancer | Phase 1 / Phase 2 | Unknown | Butantan Institute | 618 | 2021-05-01 | 2021-04-08 |
| RFA Plus Carrizumab vs Carrizumab Alone for HCC radiofrequency ablation - Tumor Immunity, Immunosuppression | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 120 | 2020-08-01 | 2020-07-08 |
| NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Thymoglobulin, Fludarabine, Cyclophosphamide - Severe Aplastic Anemia, Aplastic Anemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 21 | 2016-09-01 | 2022-07-12 |
| Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy Belatacept, Hand transplant - Immunosuppression | Phase 2 | Recruiting | Linda Cendales | 50 | 2015-03-01 | 2026-04-09 |
| Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression. Extracorporeal Photopheresis Procedure (FEC) - Liver Transplantation, Immunosuppression | Phase 1 / Phase 2 | Completed | Red de Terapia Celular | 10 | 2013-04-01 | 2017-03-30 |
| Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients Immunosuppression withdrawal - Liver Transplant Recipients, Liver Transplantation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 161 | 2012-08-14 | 2019-10-07 |
| TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs TBE-vaccine, Vaccination against TBE - Rheumatoid Arthritis, Exposed to TBE-virus | Phase 2 | Completed | Sormland County Council, Sweden | 68 | 2010-05-01 | 2011-05-25 |
| Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients inactivated non adjuvanted pandemic H1N1 vaccine - Renal Transplant Recipients, Immunosuppression | Phase 2 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 122 | 2009-11-01 | 2026-02-19 |
| Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients Vaccination with VZV vaccine - Liver Disease, Immunosuppression | Phase 2 / Phase 3 | Unknown | University Hospital, Geneva | 80 | 2007-06-01 | 2020-09-18 |
| Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention Dietary intervention - supplements - Immunosuppression, Hyperlipidemias | Phase 1 / Phase 2 | Completed | University of Alberta | 46 | 2005-11-01 | 2009-07-28 |
| Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis Daclizumab - Anterior Uveitis, Arthritis, Juvenile Idiopathic | Phase 2 | Completed | National Eye Institute (NEI) | 6 | 2005-08-01 | 2017-01-30 |
| Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients Alemtuzumab, Tacrolimus, Mycophenolate mofetil - Kidney Failure, Chronic, Kidney Transplantation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 35 | 2005-01-01 | 2017-01-02 |
Showing 20 of 21. Sign in to see all of them.
Arthritis, Rheumatoid (2) · COVID-19 (2) · Anemia, Aplastic (1) · Arthritis, Juvenile (1) · Bone Marrow Failure Disorders (1) · Carcinoma, Hepatocellular (1) · Cardiovascular Diseases (1) · Chickenpox (1) · Critical Illness (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Graft vs Host Disease (1) · Hyperlipidemias (1) · Iritis (1) · Kidney Diseases (1)
Immune System Diseases (7) · Autoimmune Diseases (5) · Connective Tissue Diseases (4) · Infections (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Skin and Connective Tissue Diseases (4) · Arthritis (3) · Digestive System Diseases (3) · Disease Attributes (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3)
Mycophenolic Acid (2) · Sirolimus (2) · Tacrolimus (2) · 2019-nCoV Vaccine mRNA-1273 (1) · ALT-803 (1) · Abatacept (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · COVID-19 Vaccines (1) · Cyclophosphamide (1) · Daclizumab (1) · FEC protocol (1) · Histamine (1) · Interleukin-2 (1) · Kidney Transplantation (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Ayman Al Jurdi, MD (1) · Brigham and Women's Hospital (1) · Butantan Institute (1) · ImmunityBio, Inc. (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Linda Cendales (1) · National Eye Institute (NEI) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Paul R Fortin (1) · Peking Union Medical College Hospital (1) · Red de Terapia Celular (1) · Sahlgrenska University Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (9) · Canada (3) · Brazil (1) · China (1) · Finland (1) · France (1) · Spain (1) · Sweden (1) · Switzerland (1)
A. John Barrett, M.D. (1) · Amy E DeZern, MD (1) · Andreas Muth (1) · Ayman Al Jurdi, MD (1) · Freddy Caldera, DO, MS (1) · J Bucuvalas, M.D. (1) · Jamil Azzi, MD, PhD (1) · Klara M Posfay-Barbe, MD, MS (1) · Lars Rombo, MD Professor (1) · Linda Cendales, MD (1) · Michael T Clandinin, PhD (1) · Paul R Fortin, MD,MPH,FRCPC (1) · Ricardo Palacios, MD, PhD (1) · S Feng, M.D., Ph.D. (1) · William Harmon, MD (1)
PMID 19664754, PMID 22052056, PMID 23065508, PMID 23103195, PMID 23524640, PMID 32343796, PMID 32786149, PMID 33280227, PMID 35819312, PMID 37084383
2009 (1), U01AI100807 (1)